Potent diuretic effects of prednisone in heart failure patients with refractory diuretic resistance

Canadian Journal of Cardiology

Volumn 23, Issue 11, 2007, Pages 865-868

  Liu, Chao ^a   Liu, Gang ^a   Zhou, Caixia ^a   Ji, Zhenguo ^a   Zhen, Yuzhi ^a   Liu, Kunshen ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Diuretic resistance; Furosemide; Heart failure; Prednisone; Renal function; Spironolactone

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ELECTROLYTE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INOTROPIC AGENT; LOOP DIURETIC AGENT; NITRATE; PREDNISONE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; GLUCOCORTICOID;

ADD ON THERAPY; ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DIURETIC ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; ELECTROLYTE BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HOSPITAL DISCHARGE; HUMAN; HYPERGLYCEMIA; HYPERVOLEMIA; KIDNEY FUNCTION; MALE; URINE VOLUME; WEIGHT REDUCTION; BLOOD; DIURESIS; DRUG EFFECT; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

CREATININE; DIURESIS; DIURETICS; FEMALE; FUROSEMIDE; GLOMERULAR FILTRATION RATE; GLUCOCORTICOIDS; HEART FAILURE, CONGESTIVE; HUMANS; HYDROCHLOROTHIAZIDE; KIDNEY; MALE; MIDDLE AGED; PREDNISONE; PROSPECTIVE STUDIES; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 35348911270     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(07)70840-1     Document Type: Article

References (22)

1. Krämer BK, Schweda F, Kammerl M, Riegger GA. Diuretic therapy and diuretic resistance in cardiac failure. Nephrol Dial Transplant 1999;14(Suppl 4):39-42.
2. Aguirre JA, Ibarra FR, Barontini M, Arrizurieta EE, Armando I. Effect of glucocorticoids on renal dopamine production. Eur J Pharmacol 1999;370:271-8.
3. Nevskaia TL, Shcherbinina AV, Ivanov IuI. [Effect of glucocorticoids on electrolyte excretion after expansion of the extracellular space.] Probl Endokrinol (Mosk) 1977;23:48-51.
4. Baylis C, Brenner BM. Mechanism of the glucocorticoid-induced increase in glomerular filtration rate. Am J Physiol 1978;234:F166-70.
5. Garcia R, Debinski W, Gutkowska J, et al. Gluco- and mineralocorticoids may regulate the natriuretic effect and the synthesis and release of atrial natriuretic factor by the rat atria in vivo. Biochem Biophys Res Commun 1985;131:806-14.
6. Lanier-Smith KL, Currie MG. Effect of glucocorticoids on the binding of atrial natriuretic peptide to endothelial cells. Eur J Pharmacol 1990;178:105-9.
7. De Matteo R, May CN. Glucocorticoid-induced renal vasodilatation is mediated by a direct renal action involving nitric oxide. Am J Physiol 1997;273:R1972-9.
8. May CN, Bednarik JA. Regional hemodynamic and endocrine effects of aldosterone, and cortisol in conscious sheep. Comparison with the effects of corticotropin. Hypertension 1995;26:294-300.
9. Kanda K, Ogawa K, Miyamoto N, Hatano T, Seo H, Matsui N. Potentiation of atrial natriuretic peptide-stimulated cyclic guanosine monophosphate formation by glucocorticoids in cultured rat renal cells. Br J Pharmacol 1989;96:795-800.
10. Damjancic P, Vierhapper H. Permissive action of glucocorticoid substitution therapy on the effects of atrial natriuretic peptide (hANP) in patients with adrenocortical insufficiency. Exp Clin Endocrinol 1990;95:315-21.
11. Yamaji T, Ishibashi M, Yamada A, et al. Plasma levels of atrial natriuretic hormone in Cushing's syndrome. J Clin Endocrinol Metab 1988;67:348-52.
12. Grapsa E, Alexopoulos GP, Margari Z, Terrovitis JV, Kontoyannis DA, Nanas JN. Ultrafiltration in the treatment of severe congestive heart failure. Int Urol Nephrol 2004;36:269-72.
13. Iorio L, De Santo LS, Violi F. Hemodialitic treatment of cardiac failure. Semin Nephrol 2001;21:278-81.
14. Ragazzoni E, Sacco A, Cusinato S, et al. [Heart failure resistant to drug therapy. Nephrologic approach.] Minerva Urol Nefrol 1998;50:133-8.
15. Iorio L, Simonelli R, Nacca RG, DeSanto LS. Daily hemofiltration in severe heart failure. Kidney Int Suppl 1997;59:S62-5.
16. Torre-Amione G. Immune activation in chronic heart failure. Am J Cardiol 2005;95:3C-8C,38C-40C.
17. Parrillo JE, Cunnion RE, Epstein SE, et al. A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 1989;321:1061-8.
18. Liu C, Chen J, Liu K. Immunosuppressive treatment for inflammatory cardiomyopathy: Meta-analysis of randomized controlled trials. Int Heart J 2005;46:113-22.
19. Brater DC. Diuretic therapy. N Engl J Med 1998;339:387-95.
20. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543-51.
21. van Vliet AA, Donker AJ, Nauta JJ, Verheugt FW. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol 1993;71:21A-8A.
22. Liu C, Chen H, Zhou C, et al. Potent potentiating diuretic effects of prednisone in congestive heart failure. J Cardiovasc Pharmacol 2006;48:173-6.